RCOG | Endometrial hyperplasia

28th April 2016 by Louise Hudman

RCOG | Endometrial hyperplasia

This is a new guideline from RCOG on diagnosing and managing endometrial hyperplasia. This is a very common condition, so highly relevant for us and I had no idea on some of the management options. I am therefore doing a general summary.

Types

  • Endometrial Hyperplasia without atypia – fewer than 5% will progress to cancer over 20 yrs and most regress spontaneously.
  • Endometrial Hyperplasia with atypia – there is a much high risk of cancer (8% at 4 yrs, 12% at 9 yrs and 27% at 19 yrs and concomitant cancer is found in 43% of women at hysterectomy).

Risk Factors

Oestrogen exposure, whether exogenous (tamoxifen / oestrogen only HRT) or endogenous (obesity, PCOS or perimenopause with anovulation or estrogen secreting tumours).

[Tweet “Obesity and PCOS are both risk factors for endometrial hyperplasia”]By Nephron (Own work) [CC BY-SA 3.0 ) or GFDL , via Wikimedia Commons

Symptoms

  • Heavy menstrual bleeding (beware the over 45s)
  • IMB
  • Irregular bleeding
  • Unscheduled bleeding on HRT
  • Postmenopausal bleeding

 Investigations

  • Endometrial biopsy
  • Hysteroscopic Biopsy (if above undiagnostic or if hyperplasia is found on a polyp)
  • USS transvaginal

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I am all set up and running on LocumDeck. I'm very impressed by how efficient and smooth it seems."

Dr Paula Zukowski

Dr Paula Zukowski

See the full list of features within our NASGP membership plans

Membership